Zobrazeno 1 - 10
of 79
pro vyhledávání: '"Leandro Blas"'
Autor:
Leandro Blas, Masaki Shiota
Publikováno v:
Clinical and Translational Discovery, Vol 4, Iss 1, Pp n/a-n/a (2024)
Externí odkaz:
https://doaj.org/article/fb470076de3f41dc899ed7429e81d5a0
Autor:
Leandro Blas, Masaki Shiota, Shohei Nagakawa, Shigehiro Tsukahara, Takashi Matsumoto, Ken Lee, Keisuke Monji, Eiji Kashiwagi, Junichi Inokuchi, Masatoshi Eto
Publikováno v:
Asian Journal of Urology, Vol 10, Iss 1, Pp 81-88 (2023)
Objective: There are many models to predict extracapsular extension (ECE) in patients with prostate cancer. We aimed to externally validate several models in a Japanese cohort. Methods: We included patients treated with robotic-assisted radical prost
Externí odkaz:
https://doaj.org/article/413df8fe86c246838d5aa77174dc0391
Autor:
Shigetomo Yamada, Masaki Shiota, Leandro Blas, Takashi Matsumoto, Eiji Kashiwagi, Ario Takeuchi, Junichi Inokuchi, Ken-ichiro Shiga, Akira Yokomizo, Masatoshi Eto
Publikováno v:
Prostate International, Vol 10, Iss 1, Pp 50-55 (2022)
Background: Androgen receptor pathway inhibitors (ARPIs) such as abiraterone and enzalutamide have been shown to prolong survival in patients with advanced prostate cancer. However, there is limited evidence on the anticancer effect of a reduced dose
Externí odkaz:
https://doaj.org/article/bf0c9b5ed77f474e89a68a8d22bbbe84
Autor:
Sotaro Chikamatsu, Masaki Shiota, Shigetomo Yamada, Leandro Blas, Takashi Matsumoto, Eiji Kashiwagi, Junichi Inokuchi, Ken-ichiro Shiga, Akira Yokomizo, Masatoshi Eto
Publikováno v:
Prostate International, Vol 10, Iss 1, Pp 7-13 (2022)
Background: The CHAARTED and LATITUDE trials demonstrated a survival benefit of docetaxel and abiraterone for hormone-sensitive prostate cancer. In this study, we examined the impact of the risk stratification criteria used in the CHAARTED and LATITU
Externí odkaz:
https://doaj.org/article/8610c69ac79a467c98ae471751c6ee74
Autor:
Florencia Secchiari, Sol Yanel Nuñez, Jessica Mariel Sierra, Andrea Ziblat, María Victoria Regge, Ximena Lucía Raffo Iraolagoitia, Agustín Rovegno, Carlos Ameri, Fernando Pablo Secin, Nicolás Richards, Hernando Ríos Pita, Gonzalo Vitagliano, Luis Rico, Mauro Mieggi, Florencia Frascheri, Nicolás Bonanno, Leandro Blas, Aldana Trotta, Adrián David Friedrich, Mercedes Beatriz Fuertes, Carolina Inés Domaica, Norberto Walter Zwirner
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
NKG2D is a major natural killer (NK) cell-activating receptor that recognizes eight ligands (NKG2DLs), including MICA, and whose engagement triggers NK cell effector functions. As NKG2DLs are upregulated on tumor cells but tumors can subvert the NKG2
Externí odkaz:
https://doaj.org/article/1adb248fdaf140c9b28258767763461f
Publikováno v:
Cancer Treatment and Research Communications, Vol 32, Iss , Pp 100606- (2022)
Since 1941, the standard treatment for metastatic castration-sensitive prostate cancer (mCSPC) was androgen deprivation therapy (ADT) by surgical or medical castration with or without first-generation antiandrogen. However, the efficacy of ADT does n
Externí odkaz:
https://doaj.org/article/3e011d763df84dfdad33ed9d4f08394f
Autor:
Masaki Shiota, Leandro Blas
Publikováno v:
Current Cancer Drug Targets. 23:428-432
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1712f7936f039f7c2d4450622a138678
https://doi.org/10.2174/1568009623666230220121610
https://doi.org/10.2174/1568009623666230220121610
Autor:
Masashi Kaitsumaru, Masaki Shiota, Dai Takamatsu, Leandro Blas, Takashi Matsumoto, Junichi Inokuchi, Yoshinao Oda, Masatoshi Eto
Publikováno v:
International Cancer Conference Journal. 12:131-136
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e7e6fa4d94647c6239a206eed4ea455
https://doi.org/10.1007/s13691-022-00592-5
https://doi.org/10.1007/s13691-022-00592-5
Autor:
Leandro Blas, Masaki Shiota, Dai Takamatsu, Fumio Kinoshita, Takashi Matsumoto, Ken Lee, Keisuke Monji, Eiji Kashiwagi, Junichi Inokuchi, Masatoshi Eto
Publikováno v:
World Journal of Urology. 41:43-50
Conditional survival represents the probability of subsequent survival given that patients have already survived a certain length of time. Several models predict biochemical recurrence (BCR) after radical prostatectomy. However, none of them include
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0491309668f25eaee8b722fe95db076
https://doi.org/10.1007/s00345-022-04245-3
https://doi.org/10.1007/s00345-022-04245-3
Autor:
Leandro Blas, Masaki Shiota, Shigehiro Tsukahara, Shohei Nagakawa, Takashi Matsumoto, Masatoshi Eto
Publikováno v:
Clinical Genitourinary Cancer; Feb2024, Vol. 22 Issue 1, pe122-e127.e1, 7p